ALPS Advisors’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3,178
| Closed | -$559K | – | 1050 |
|
|
2025
Q4 | $559K | Buy |
3,178
+35
| +1% | +$5.72K | ﹤0.01% | 691 |
|
|
2025
Q3 | $440K | Buy |
3,143
+612
| +24% | +$82.7K | ﹤0.01% | 837 |
|
|
2025
Q2 | $318K | Buy |
2,531
+31
| +1% | +$3.86K | ﹤0.01% | 918 |
|
|
2025
Q1 | $342K | Buy |
+2,500
| New | +$357K | ﹤0.01% | 822 |
|
|
2023
Q3 | – | Sell |
-1,240
| Closed | -$353K | – | 994 |
|
|
2023
Q2 | $353K | Buy |
1,240
+10
| +0.8% | +$2.98K | ﹤0.01% | 719 |
|
|
2023
Q1 | $342K | Buy |
+1,230
| New | +$340K | ﹤0.01% | 708 |
|
|
2020
Q2 | – | Sell |
-722
| Closed | -$228K | – | 782 |
|
|
2020
Q1 | $228K | Sell |
722
-744
| -51% | -$226K | ﹤0.01% | 661 |
|
|
2019
Q4 | $435K | Sell |
1,466
-63
| -4% | -$17.5K | ﹤0.01% | 530 |
|
|
2019
Q3 | $356K | Buy |
1,529
+305
| +25% | +$71K | ﹤0.01% | 677 |
|
|
2019
Q2 | $286K | Sell |
1,224
-313
| -20% | -$72.3K | ﹤0.01% | 850 |
|
|
2019
Q1 | $363K | Sell |
1,537
-7,153
| -82% | -$2.25M | ﹤0.01% | 845 |
|
|
2018
Q4 | $2.62M | Buy |
8,690
+3,167
| +57% | +$1.01M | 0.02% | 196 |
|
|
2018
Q3 | $1.95M | Buy |
5,523
+3,638
| +193% | +$1.25M | 0.01% | 254 |
|
|
2018
Q2 | $547K | Sell |
1,885
-352
| -16% | -$99K | ﹤0.01% | 526 |
|
|
2018
Q1 | $613K | Buy |
2,237
+435
| +24% | +$135K | ﹤0.01% | 416 |
|
|
2017
Q4 | $574K | Sell |
1,802
-198
| -10% | -$63.5K | ﹤0.01% | 423 |
|
|
2017
Q3 | $626K | Sell |
2,000
-109
| -5% | -$32.3K | ﹤0.01% | 331 |
|
|
2017
Q2 | $572K | Buy |
2,109
+209
| +11% | +$55.3K | ﹤0.01% | 385 |
|
|
2017
Q1 | $519K | Buy |
1,900
+177
| +10% | +$50K | ﹤0.01% | 368 |
|
|
2016
Q4 | $489K | Sell |
1,723
-113
| -6% | -$33.5K | ﹤0.01% | 424 |
|
|
2016
Q3 | $575K | Sell |
1,836
-228
| -11% | -$67.5K | ﹤0.01% | 255 |
|
|
2016
Q2 | $499K | Buy |
2,064
+204
| +11% | +$53.8K | ﹤0.01% | 268 |
|
|
2016
Q1 | $484K | Buy |
1,860
+176
| +10% | +$46.5K | 0.01% | 235 |
|
|
2015
Q4 | $516K | Sell |
1,684
-172
| -9% | -$49.4K | 0.01% | 410 |
|
|
2015
Q3 | $5.42K | Buy |
1,856
+510
| +38% | +$168K | 0.01% | 273 |
|
|
2015
Q2 | $544K | Buy |
1,346
+30
| +2% | +$12K | ﹤0.01% | 396 |
|
|
2015
Q1 | $556K | Sell |
1,316
-330
| -20% | -$130K | ﹤0.01% | 270 |
|
|
2014
Q4 | $559K | Sell |
1,646
-347
| -17% | -$112K | ﹤0.01% | 361 |
|
|
2014
Q3 | $659K | Buy |
1,993
+206
| +12% | +$67.9K | 0.01% | 189 |
|
|
2014
Q2 | $563K | Buy |
1,787
+57
| +3% | +$17.2K | ﹤0.01% | 462 |
|
|
2014
Q1 | $529K | Sell |
1,730
-284
| -14% | -$90.2K | 0.01% | 536 |
|
|
2013
Q4 | $630K | Buy |
2,014
+980
| +95% | +$253K | 0.01% | 186 |
|
|
2013
Q3 | $249K | Buy |
+1,034
| New | +$231K | ﹤0.01% | 444 |
|
Other funds holding BIIB
VCM
VPM
ALPS Advisors's BIIB Position: Q1 2026 in Review
ALPS Advisors sold out of Biogen (BIIB) in Q1 2026, closing a stake of 3,178 shares — an estimated $559K sold.
ALPS Advisors first reported a position in BIIB in Q3 2013 and held it in 33 quarters. The position peaked at $2.62M in Q4 2018. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- ALPS Advisors reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
- ALPS Advisors sold 3,178 Biogen shares in Q1 2026, an estimated $559K.
- ALPS Advisors first reported a position in Biogen in Q3 2013 and held it in 33 quarters.
- ALPS Advisors's Biogen position peaked at $2.62M in Q4 2018.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.